L & S Advisors Inc Invests $4.07 Million in CVS Health Corporation $CVS

Key Points

• L & S Advisors Inc opened a new position in CVS Health during the fourth quarter, buying 51,275 shares worth about $4.07 million.
• Institutional interest in CVS remains high, with 80.66% of shares held by institutions and hedge funds, while analysts continue to lean positive on the stock with a Moderate Buy consensus and a target price of $98.08.
• CVS recently posted better-than-expected Q1 2026 results, with EPS of $2.57 and revenue of $100.43 billion, and it reaffirmed full-year EPS guidance of 7.30 to 7.50.

L & S Advisors Inc acquired a new position in shares of CVS Health Corporation (NYSE:CVS - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 51,275 shares of the pharmacy operator's stock, valued at approximately $4,069,000.

Several other institutional investors and hedge funds have also made changes to their positions in CVS. Soltis Investment Advisors LLC boosted its position in shares of CVS Health by 54.5% in the 4th quarter. Soltis Investment Advisors LLC now owns 8,044 shares of the pharmacy operator's stock valued at $638,000 after purchasing an additional 2,836 shares during the period. iA Global Asset Management Inc. acquired a new stake in shares of CVS Health in the 4th quarter valued at about $3,364,000. Barr E S & Co. acquired a new stake in shares of CVS Health in the 4th quarter valued at about $613,000. Canada Post Corp Registered Pension Plan boosted its position in shares of CVS Health by 53.3% in the 4th quarter. Canada Post Corp Registered Pension Plan now owns 34,903 shares of the pharmacy operator's stock valued at $2,770,000 after purchasing an additional 12,130 shares during the period. Finally, Lawood & Co. acquired a new stake in shares of CVS Health in the 4th quarter valued at about $256,000. 80.66% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on CVS shares. The Goldman Sachs Group upped their target price on CVS Health from $95.00 to $97.00 and gave the company a "buy" rating in a research report on Thursday, February 12th. JPMorgan Chase & Co. upped their target price on CVS Health from $101.00 to $111.00 and gave the company an "overweight" rating in a research report on Tuesday, May 12th. Robert W. Baird upped their target price on CVS Health from $92.00 to $94.00 and gave the company an "outperform" rating in a research report on Wednesday, April 15th. TD Cowen upped their target price on CVS Health from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Monday, May 11th. Finally, Royal Bank Of Canada upped their target price on CVS Health from $93.00 to $107.00 and gave the company an "outperform" rating in a research report on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $98.08.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Morgan Stanley raised its price target on CVS Health and kept an overweight rating, signaling confidence in further upside after the company’s stronger-than-expected quarterly results. Morgan Stanley Issues Positive Forecast for CVS Health NYSE: CVS Stock Price
• Positive Sentiment: Argus also lifted its outlook for CVS Health, adding to the wave of analyst support that may be helping shares move higher. Argus Issues Positive Forecast for CVS Health NYSE: CVS Stock Price
• Positive Sentiment: CVS reported solid Q1 2026 earnings recently, beating estimates on both revenue and adjusted EPS, which continues to drive investor optimism about execution and valuation. Here is Why CVS Health (CVS) is One of the Cheap Stocks to Buy For the Next 10 Years
• Positive Sentiment: CVS and WGU launched an online pre-pharmacy degree program to help build a stronger pharmacist pipeline, a move that could support long-term staffing and service growth. CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
• Neutral Sentiment: CVS advanced its portfolio reset by selling Omnicare after bankruptcy court approval, which simplifies the business and removes an underperforming unit, but also confirms ongoing restructuring. CVS Refocuses On Core Health Platform With Omnicare Sale And Drone Rollout
• Neutral Sentiment: CVS also highlighted community and brand-building initiatives in Rhode Island, including its economic impact report and expanded WIC acceptance, which are positive for reputation but less likely to move the stock on their own. CVS Health’s Annual Impact in Rhode Island

Insiders Place Their Bets

In other news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company's stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.85% of the company's stock.

CVS Health Stock Down 1.2%

CVS Health stock opened at $95.95 on Friday. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $98.43. The stock has a 50 day moving average of $78.71 and a two-hundred day moving average of $78.59. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $122.42 billion, a price-to-earnings ratio of 42.27, a PEG ratio of 0.94 and a beta of 0.60.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts' consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion during the quarter, compared to analysts' expectations of $94.99 billion. During the same period last year, the firm earned $2.25 EPS. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health's dividend payout ratio (DPR) is presently 117.18%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.